BACKGROUND: Urinary symptoms are common, disabling and generally unresponsive to treatment in Parkinson´s disease (PD). Safinamide is approved as an add-on therapy to levodopa to improve fluctuations. METHODS: Retrospective analysis of electronic records of nondemented PD patients seen consecutively in a Movement Disorders Unit (November 2018-February 2019). All were assessed with Scale for Outcomes in Parkinson's disease for Autonomic Symptoms-Urinary subscale (SCOPA-AUT-U) by the attending neurologist, and a month afterwards by an independent researcher blinded to treatment and clinical records in a routine clinical practice setting. Clinical variables were compared among patients who were prescribed safinamide (SA+) for the treatment of motor fluctuations and those with different treatment regimes (SA-). RESULTS: From 169 patients screened initially, 54 were excluded due to severe incontinence, absence of urinary symptoms or previous safinamide treatment. Thirty-five patients were included in SA+ and 79 in SA-. Both groups were comparable in terms of clinical variables, except in basal urinary symptoms, with more severity in the SA+ group. In the follow-up assessment, total SCOPA-AUT-U, as well as urgency, incontinence, frequency and nocturia subscales improved significantly in the SA+ group, while the SA- group remained unchanged. CONCLUSIONS: Safinamide could be helpful in the improvement of urinary symptoms in PD.
BACKGROUND: Urinary symptoms are common, disabling and generally unresponsive to treatment in Parkinson´s disease (PD). Safinamide is approved as an add-on therapy to levodopa to improve fluctuations. METHODS: Retrospective analysis of electronic records of nondemented PDpatients seen consecutively in a Movement Disorders Unit (November 2018-February 2019). All were assessed with Scale for Outcomes in Parkinson's disease for Autonomic Symptoms-Urinary subscale (SCOPA-AUT-U) by the attending neurologist, and a month afterwards by an independent researcher blinded to treatment and clinical records in a routine clinical practice setting. Clinical variables were compared among patients who were prescribed safinamide (SA+) for the treatment of motor fluctuations and those with different treatment regimes (SA-). RESULTS: From 169 patients screened initially, 54 were excluded due to severe incontinence, absence of urinary symptoms or previous safinamide treatment. Thirty-five patients were included in SA+ and 79 in SA-. Both groups were comparable in terms of clinical variables, except in basal urinary symptoms, with more severity in the SA+ group. In the follow-up assessment, total SCOPA-AUT-U, as well as urgency, incontinence, frequency and nocturia subscales improved significantly in the SA+ group, while the SA- group remained unchanged. CONCLUSIONS:Safinamide could be helpful in the improvement of urinary symptoms in PD.
Authors: L Brusa; S Musco; G Bernardi; C Iani; M Pierantozzi; P Stanzione; A Stefani; E Finazzi Agro' Journal: Parkinsonism Relat Disord Date: 2014-04-28 Impact factor: 4.891
Authors: F Valldeoriola; F Grandas; J M Arbelo; M Blázquez Estrada; M Calopa Garriga; V M Campos-Arillo; P J Garcia Ruiz; J C Gómez Esteban; C Leiva Santana; J C Martínez Castrillo; P Mir; A Salvador Aliaga; F Vivancos Matellano; R M Yáñez Baña Journal: Neurologia (Engl Ed) Date: 2018-07-30
Authors: Daniel J Burdick; Brenna Cholerton; G S Watson; Andrew Siderowf; John Q Trojanowski; Daniel Weintraub; Beate Ritz; Shannon L Rhodes; Renecca Rausch; Stewart A Factor; Cathy Wood-Siverio; Joseph F Quinn; Kathryn A Chung; Sindhu Srivatsal; Karen L Edwards; Thomas J Montine; Cyrus P Zabetian; James B Leverenz Journal: Mov Disord Date: 2014-07-29 Impact factor: 10.338
Authors: Diego Santos García; Carmen Labandeira Guerra; Rosa Yáñez Baña; Maria Icíar Cimas Hernando; Iria Cabo López; Jose Manuel Paz Gonález; Maria Gemma Alonso Losada; María José González Palmás; Cristina Martínez Miró Journal: Brain Sci Date: 2021-03-02